PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals announced updated interim data from its PYNNACLE Phase 2 trial evaluating rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutations. The trial showed a 46% overall response rate with a median duration of response of 10 months. The FDA recently supported the company's plan for accel…